BioBridge Global’s R&D Analytical Development team now has a specialized lab to call their own.
The team has qualified assays for RUO and cGMP use including three different safety assays and cell characterization assays (including over 30 different flow markers), 25 plus cytokine markers and 15 plus viral markers targeted by PCR.
“We’ve done a good amount, and come a long way,” Anthony Trinh, Ph.D., Senior Manager Analytical Development, said.
With a designated space, the Analytical Development team will continue its lifesaving mission. The new lab is equipped with state-of-the-art equipment to further develop assays.
The team’s primary focus is to develop, qualify and validate assays for BioBridge Global and its clients in the Advanced Therapies field.
“Researchers, scientists, and therapeutic developers across many spectrums must create these analytical assays to make sure that medicine does what it is supposed to do and is safe for people to use,” Trinh said.
Trinh’s Analytical Development team consists of 3 scientists: Ileana Pedraza, M.S., Xiaoli Li, M.S, and Sidney Carter, Ph.D.
“We are cross-trained, so that way anyone can be available to answer questions,” Trinh said. “For instance, Sydney is our resident flow expert. Xiaoli is our resident PCR expert, and Ileana is our ELISA and bioassay expert, but we’re all cross trained. The team looks forward to further expanding their development and qualification activities to support the growing Advanced Therapies industry.
This will be done by broadening the capabilities of the lab and moving projects and assays quicker into the production labs.
To learn about our analytical development capabilities, visit Research & Development.
